Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

被引:5
|
作者
Huang, Yunda [1 ,2 ,3 ]
Zhang, Yuanyuan [1 ]
Seaton, Kelly E. [4 ]
De Rosa, Stephen [1 ]
Heptinstall, Jack [4 ]
Carpp, Lindsay N. [1 ]
Randhawa, April Kaur [1 ]
McKinnon, Lyle R. [5 ,6 ,7 ]
McLaren, Paul [5 ,6 ]
Viegas, Edna [8 ]
Gray, Glenda E. [9 ,10 ]
Churchyard, Gavin [11 ,12 ]
Buchbinder, Susan P. [13 ,14 ,15 ]
Edupuganti, Srilatha [16 ]
Bekker, Linda-Gail [17 ]
Keefer, Michael C. [18 ]
Hosseinipour, Mina C. [19 ,20 ]
Goepfert, Paul A. [21 ]
Cohen, Kristen W. [1 ]
Williamson, Brian D. [1 ,22 ]
McElrath, M. Juliana [1 ]
Tomaras, Georgia D. [4 ]
Thakar, Juilee [23 ]
Kobie, James J. [21 ]
机构
[1] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA
[3] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[4] Duke Univ, Ctr Human Syst Immunol, Dept Surg, Sch Med, Durham, NC USA
[5] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[6] Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, Winnipeg, MB, Canada
[7] Ctr AIDS Program Res South Africa CAPRISA, Durban, South Africa
[8] Inst Nacl Saude, Maputo, Mozambique
[9] Univ Witwatersrand, Fac Hlth Sci, Perinatal HIV Res Unit, Johannesburg, South Africa
[10] South African Med Res Council, Cape Town, South Africa
[11] Aurum Inst, Johannesburg, South Africa
[12] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
[13] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA
[14] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[15] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA
[16] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA
[17] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa
[18] Univ Rochester, Dept Med, Infect Dis Div, Sch Med & Dent, Rochester, NY USA
[19] Univ North Carolina Project, Lilongwe, Malawi
[20] Univ N Carolina, Sch Med, Inst Global Hlth & Infect Dis, Dept Med, Chapel Hill, NC USA
[21] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA
[22] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[23] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY USA
来源
EBIOMEDICINE | 2022年 / 84卷
关键词
Baseline characteristics; SuperLearner; Variable importance measurements; Vaccine response heterogeneity; Antibody; CD4+ T cell; CELL RESPONSES; DOUBLE-BLIND; CORRELATES ANALYSIS; EFFICACY TRIAL; T-CELLS; PROTECTION; ANTIBODIES; BINDING; PLASMA; HETEROGENEITY;
D O I
10.1016/j.ebiom.2022.104271
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The identification of baseline host determinants that associate with robust HIV-1 vaccine-induced immune responses could aid HIV-1 vaccine development. We aimed to assess both the collective and relative performance of baseline characteristics in classifying individual participants in nine different Phase 1-2 HIV-1 vaccine clinical trials (26 vaccine regimens, conducted in Africa and in the Americas) as High HIV-1 vaccine responders. Methods This was a meta-analysis of individual participant data, with studies chosen based on participant-level (vs. study-level summary) data availability within the HIV-1 Vaccine Trials Network. We assessed the performance of 25 baseline characteristics (demographics, safety haematological measurements, vital signs, assay background measurements) and estimated the relative importance of each characteristic in classifying 831 participants as High (defined as within the top 25th percentile among positive responders or above the assay upper limit of quantification) versus Non-High responders. Immune response outcomes included HIV-1-specific serum IgG binding antibodies and Env-specific CD4+ T-cell responses assessed two weeks post-last dose, all measured at central HVTN laboratories. Three variable importance approaches based on SuperLearner ensemble machine learning were considered. Findings Overall, 30.1%, 50.5%, 36.2%, and 13.9% of participants were categorized as High responders for gp120 IgG, gr140 IgG, gp41 IgG, and Env-specific CD4+ T-cell vaccine-induced responses, respectively. When including all baseline characteristics, moderate performance was achieved for the classification of High responder status for the binding antibody responses, with cross-validated areas under the ROC curve (CV-AUC) of 0.72 (95% CI: 0.68, 0.76) for gp120 IgG, 0.73 (0.69, 0.76) for gr140 IgG, and o.67 (95% CI: 0.63, 0.72) for gp41 IgG. In contrast, the collection of all baseline characteristics yielded little improvement over chance for predicting High Env-specific CD4+ T-cell responses [CV-AUC: 0.53 (0.48, 0.58)]. While estimated variable importance patterns differed across the three approaches, female sex assigned at birth, lower height, and higher total white blood cell count emerged as significant predictors of High responder status across multiple immune response outcomes using Approach 1. Of these three baseline variables, total white blood cell count ranked highly across all three approaches for predicting vaccine-induced gp41 and gr140 High responder status. Interpretation The identified features should be studied further in pursuit of intervention strategies to improve vaccine responses and may be adjusted for in analyses of immune response data to enhance statistical power. Copyright (C) 2022 The Author(s). Published by Elsevier B.V.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates
    Lee, SA
    Orque, R
    Escarpe, PA
    Peterson, ML
    Good, JW
    Zaharias, EM
    Berman, PW
    Sheppard, HW
    Shibata, R
    VACCINE, 2001, 20 (3-4) : 563 - 576
  • [32] MODULATING THE TUMOR MICROENVIRONMENT BY A TARGETING TGFB1 WITH VACCINE-INDUCED IMMUNE RESPONSES
    Weinert, Brian
    Hannibal, Tine
    Patel, Preeyam
    Martinenaite, Evelina
    Chapellier, Marion
    Carretta, Marco
    Alavi, Alireza
    Pedersen, Ayako
    Al-Hajj, Muhammad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1226 - A1226
  • [33] HIV-1 RECOMBINANT GP160 VACCINE-INDUCED ANTIBODIES IN SERUM AND SALIVA
    GORSE, GJ
    ROGERS, JH
    PERRY, JE
    NEWMAN, FK
    FREY, SE
    PATEL, GB
    BELSHE, RB
    SCHWARTZ, DH
    CLEMENTS, ML
    KEEFER, M
    DOLIN, R
    MCELRATH, J
    COREY, L
    GRAHAM, BS
    WRIGHT, PF
    STABLEIN, DM
    MATTHEWS, TJ
    BOLOGNESI, D
    MESTECKY, J
    WALKER, MC
    FAST, PE
    VACCINE, 1995, 13 (02) : 209 - 214
  • [34] Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV
    Kim, JJ
    Simbiri, KA
    Sin, JI
    Dang, KS
    Oh, J
    Dentchev, T
    Lee, D
    Nottingham, LK
    Chalian, AA
    McCallus, D
    Ciccarelli, R
    Agadjanyan, MG
    Weiner, DB
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (01): : 77 - 84
  • [35] Human HIV-1 Vaccine Induced Antibody Durability and Env IgG3 Responses
    Seaton, K.
    Yates, N.
    Williams, W.
    Liao, L.
    deCamp, A.
    Fong, Y.
    Montefiori, D.
    Spearman, P.
    Elizaga, M.
    Barnett, S.
    Koutsoukos, M.
    Bourguignon, P.
    McElrath, J.
    Corey, L.
    Michael, N.
    Pitisuttithum, P.
    Rerks-Ngarm, S.
    Kim, J.
    Voss, G.
    Gilbert, P.
    Haynes, B.
    Tomaras, G.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A187 - A187
  • [36] Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
    Zolla-Pazner, Susan
    Edlefsen, Paul T.
    Rolland, Morgane
    Kong, Xiang-Peng
    deCamp, Allan
    Gottardo, Raphael
    Williams, Constance
    Tovanabutra, Sodsai
    Sharpe-Cohen, Sandra
    Mullins, James I.
    deSouza, Mark S.
    Karasavvas, Nicos
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Pitisuttihum, Punnee
    Kaewkungwal, Jaranit
    O'Connell, Robert J.
    Robb, Merlin L.
    Michael, Nelson L.
    Kim, JeromeH.
    Gilbert, Peter
    EBIOMEDICINE, 2014, 1 (01): : 37 - 45
  • [37] Vaccine Induced HIV Seropositivity/reactivity (VISP/R) among Recipients of Adenovirus Vectored HIV-1 Vaccine Prime/boost Regimens
    Kitandwe, Paul
    Farah, Bashir
    Bizimana, Jean
    Karita, Etienne
    Mutua, Gaudensia
    Mpendo, Juliet
    Omosa-Manyonyi, Gloria
    Bekker, Linda-Gail
    Gray, Glenda
    Baden, Lindsey
    Lehrman, Jennifer
    Laufer, Dagna
    Roman, Francois
    Barin, Burc
    Schmidt, Claudia
    Fast, Patricia
    Cox, Josephine
    Priddy, Frances
    Gelderblom, Huub
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 : 394 - 394
  • [38] Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial
    Kenny, A.
    Luedtke, A.
    Hyrien, O.
    Fong, Y.
    Burnham, R.
    Heptinstall, J.
    Sawant, S.
    Stanfield-Oakley, S.
    Omar, F. L.
    Khuzwayo, S.
    Dintwe, O.
    Borducchi, E.
    Pattacini, L.
    Willems, W.
    Lavreys, L.
    van Duijn, J.
    Stieh, D. J.
    Tomaka, F.
    Pau, M. G.
    Gray, G. E.
    Buchbinder, S.
    Mngadi, K.
    McElrath, M. J.
    Corey, L.
    Barouch, D. H.
    De Rosa, S. C.
    Ferrari, G.
    Andersen-Nissen, E.
    Tomaras, G.
    Gilbert, P. B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 214 - 214
  • [39] Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
    Haynes, Barton F.
    Gilbert, Peter B.
    McElrath, M. Juliana
    Zolla-Pazner, Susan
    Tomaras, Georgia D.
    Alam, S. Munir
    Evans, David T.
    Montefiori, David C.
    Karnasuta, Chitraporn
    Sutthent, Ruengpueng
    Liao, Hua-Xin
    DeVico, Anthony L.
    Lewis, George K.
    Williams, Constance
    Pinter, Abraham
    Fong, Youyi
    Janes, Holly
    DeCamp, Allan
    Huang, Yunda
    Rao, Mangala
    Billings, Erik
    Karasavvas, Nicos
    Robb, Merlin L.
    Ngauy, Viseth
    de Souza, Mark S.
    Paris, Robert
    Ferrari, Guido
    Bailer, Robert T.
    Soderberg, Kelly A.
    Andrews, Charla
    Berman, Phillip W.
    Frahm, Nicole
    De Rosa, Stephen C.
    Alpert, Michael D.
    Yates, Nicole L.
    Shen, Xiaoying
    Koup, Richard A.
    Pitisuttithum, Punnee
    Kaewkungwal, Jaranit
    Nitayaphan, Sorachai
    Rerks-Ngarm, Supachai
    Michael, Nelson L.
    Kim, Jerome H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14): : 1275 - 1286
  • [40] HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    McElrath, M. Juliana
    De Rosa, Stephen C.
    Moodie, Zoe
    Dubey, Sheri
    Kierstead, Lisa
    Janes, Holly
    Defawe, Olivier D.
    Carter, Donald K.
    Hural, John
    Akondy, Rama
    Buchbinder, Susan P.
    Robertson, Michael N.
    Mehrotra, Devan V.
    Self, Steven G.
    Corey, Lawrence
    Shiver, John W.
    Casimiro, Danilo R.
    LANCET, 2008, 372 (9653): : 1894 - 1905